Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Ocugen Announced That Dosing Is Complete In The Third Cohort Of Its Phase 1/2 GARDian Clinical Trial For OCU410ST (AAV-hRORA)—a Modifier Gene Therapy Candidate Being Developed For Stargardt Disease

Author: Benzinga Newsdesk | August 28, 2024 06:32am

Posted In: OCGN